Published in BMC Genomics on May 01, 2012
Learning dysregulated pathways in cancers from differential variability analysis. Cancer Inform (2014) 0.94
Preferential activation of the hedgehog pathway by epigenetic modulations in HPV negative HNSCC identified with meta-pathway analysis. PLoS One (2013) 0.83
Cleaved NOTCH1 Expression Pattern in Head and Neck Squamous Cell Carcinoma Is Associated with NOTCH1 Mutation, HPV Status, and High-Risk Features. Cancer Prev Res (Phila) (2015) 0.81
A new analysis approach of epidermal growth factor receptor pathway activation patterns provides insights into cetuximab resistance mechanisms in head and neck cancer. BMC Med (2012) 0.80
c-Abl modulates tumor cell sensitivity to antibody-dependent cellular cytotoxicity. Cancer Immunol Res (2014) 0.78
Identifying context-specific transcription factor targets from prior knowledge and gene expression data. IEEE Trans Nanobioscience (2013) 0.77
Capturing drug responses by quantitative promoter activity profiling. CPT Pharmacometrics Syst Pharmacol (2013) 0.75
CoGAPS matrix factorization algorithm identifies transcriptional changes in AP-2alpha target genes in feedback from therapeutic inhibition of the EGFR network. Oncotarget (2016) 0.75
Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A (1998) 192.97
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol (2004) 101.91
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med (2006) 25.67
Singular value decomposition for genome-wide expression data processing and modeling. Proc Natl Acad Sci U S A (2000) 18.42
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. J Cell Biol (1988) 16.82
Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44
Head and neck cancer. N Engl J Med (2001) 7.32
A model for measurement error for gene expression arrays. J Comput Biol (2001) 5.58
Frozen robust multiarray analysis (fRMA). Biostatistics (2010) 5.57
A novel signaling pathway impact analysis. Bioinformatics (2008) 5.06
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell (2004) 3.91
Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol (2004) 3.67
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol (2003) 2.85
p53 mutations in human immortalized epithelial cell lines. Carcinogenesis (1993) 2.82
Identification of key processes underlying cancer phenotypes using biologic pathway analysis. PLoS One (2007) 2.18
Application of Bayesian decomposition for analysing microarray data. Bioinformatics (2002) 2.11
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
Ras family signaling: therapeutic targeting. Cancer Biol Ther (2003) 1.74
Notch signaling in solid tumors. Curr Top Dev Biol (2010) 1.66
c-Ha-ras oncogene expression in immortalized human keratinocytes (HaCaT) alters growth potential in vivo but lacks correlation with malignancy. Cancer Res (1990) 1.59
Pathway analysis of expression data: deciphering functional building blocks of complex diseases. PLoS Comput Biol (2011) 1.52
Detection of treatment-induced changes in signaling pathways in gastrointestinal stromal tumors using transcriptomic data. Cancer Res (2009) 1.31
Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J Biol Chem (2000) 1.21
ErbB receptors in the biology and pathology of the aerodigestive tract. Exp Cell Res (2008) 1.17
CoGAPS: an R/C++ package to identify patterns and biological process activity in transcriptomic data. Bioinformatics (2010) 1.15
Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res (2004) 1.13
ASAP: automated sequence annotation pipeline for web-based updating of sequence information with a local dynamic database. Bioinformatics (2003) 1.11
TGFβ signaling in head and neck squamous cell carcinoma. Oncogene (2010) 1.08
Targeting EGFR resistance networks in head and neck cancer. Cell Signal (2009) 1.07
Matrix factorization for recovery of biological processes from microarray data. Methods Enzymol (2009) 1.02
Determination of strongly overlapping signaling activity from microarray data. BMC Bioinformatics (2006) 0.99
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98
Epidermal morphogenesis and keratin expression in c-Ha-ras-transfected tumorigenic clones of the human HaCaT cell line. Cancer Res (1991) 0.97
Determining transcription factor activity from microarray data using Bayesian Markov chain Monte Carlo sampling. Stud Health Technol Inform (2007) 0.85
Bayesian decomposition: analyzing microarray data within a biological context. Ann N Y Acad Sci (2004) 0.84
Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression. Mol Carcinog (1998) 0.80
Gene expression profiles as markers of aggressive disease-EGFR as a factor. Int J Radiat Oncol Biol Phys (2007) 0.80
Decreased growth inhibitory responses of squamous carcinoma cells to interferon-gamma involve failure to recruit cki proteins into cdk2 complexes. J Invest Dermatol (2001) 0.78
Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74
Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology (2008) 3.28
Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol (2012) 3.04
Radiation dose-volume effects in the brain. Int J Radiat Oncol Biol Phys (2010) 2.94
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86
Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials. J Natl Cancer Inst (2013) 2.35
Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas. J Clin Oncol (2010) 2.30
Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res (2003) 2.24
Can drugs enhance hypofractionated radiotherapy? A novel method of modeling radiosensitization using in vitro data. Int J Radiat Oncol Biol Phys (2012) 2.12
The impact of brachytherapy on prostate cancer-specific mortality for definitive radiation therapy of high-grade prostate cancer: a population-based analysis. Int J Radiat Oncol Biol Phys (2012) 2.10
Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res (2006) 2.05
Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res (2012) 2.02
A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97
Transforming growth factor beta engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab. Mol Cell Biol (2008) 1.95
Data standards for flow cytometry. OMICS (2006) 1.95
COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. Lancet Oncol (2007) 1.95
Regulation of heparin-binding EGF-like growth factor by miR-212 and acquired cetuximab-resistance in head and neck squamous cell carcinoma. PLoS One (2010) 1.77
A novel cross-disciplinary multi-institute approach to translational cancer research: lessons learned from Pennsylvania Cancer Alliance Bioinformatics Consortium (PCABC). Cancer Inform (2007) 1.76
Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer (2011) 1.76
Differentiation and definition of vascular-targeted therapies. Clin Cancer Res (2005) 1.74
Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell (2002) 1.71
Improving prognosis of glioblastoma in the 21st century: who has benefited most? Cancer (2011) 1.70
Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest (2009) 1.68
Global reactivation of epigenetically silenced genes in prostate cancer. Cancer Prev Res (Phila) (2010) 1.66
Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov (2012) 1.63
A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther (2009) 1.61
Regulation of intracellular pH in human melanoma: potential therapeutic implications. Mol Cancer Ther (2002) 1.57
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma. Oral Oncol (2013) 1.57
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients. Int J Radiat Oncol Biol Phys (2012) 1.56
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer (2003) 1.56
The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments. Cell Cycle (2011) 1.55
Inhibition of cell survival and invasive potential of colorectal carcinoma cells by the tyrosine kinase inhibitor STI571. Cancer Biol Ther (2004) 1.55
Improved survival of Japanese patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma. Int J Clin Oncol (2012) 1.55
VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys (2007) 1.55
Assessing the value of an optional radiation oncology clinical rotation during the core clerkships in medical school. Int J Radiat Oncol Biol Phys (2012) 1.54
Prognostic factors and outcomes after definitive treatment of female urethral cancer: a population-based analysis. Urology (2012) 1.53
LS-NMF: a modified non-negative matrix factorization algorithm utilizing uncertainty estimates. BMC Bioinformatics (2006) 1.53
Technique of outpatient placement of intraprostatic fiducial markers before external beam radiotherapy. Urology (2009) 1.45
Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. PLoS One (2009) 1.45
Serum microRNA biomarkers for detection of non-small cell lung cancer. PLoS One (2012) 1.43
Comparative shotgun proteomics using spectral count data and quasi-likelihood modeling. J Proteome Res (2010) 1.43
Effect of percentage of positive prostate biopsy cores on biochemical outcome in low-risk PCa treated with brachytherapy or 3D-CRT. Urology (2009) 1.43
A feed-forward loop involving protein kinase Calpha and microRNAs regulates tumor cell cycle. Cancer Res (2009) 1.43
Targeting the mechanisms of resistance to chemotherapy and radiotherapy with the cancer stem cell hypothesis. J Oncol (2010) 1.40
Suprabasal Dsg2 expression in transgenic mouse skin confers a hyperproliferative and apoptosis-resistant phenotype to keratinocytes. J Cell Sci (2007) 1.39
Epithelial tissues have varying degrees of susceptibility to Kras(G12D)-initiated tumorigenesis in a mouse model. PLoS One (2011) 1.38
Cooperative induction of a tolerogenic dendritic cell phenotype by cytokines secreted by pancreatic carcinoma cells. J Immunol (2006) 1.33
Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res (2005) 1.32
Patient-oriented cancer information on the internet: a comparison of wikipedia and a professionally maintained database. J Oncol Pract (2011) 1.31
Targeting the epidermal growth factor receptor in cancer: apoptosis takes center stage. Cancer Res (2003) 1.29
Interaction with LC8 is required for Pak1 nuclear import and is indispensable for zebrafish development. PLoS One (2009) 1.29
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators. Clin Cancer Res (2010) 1.22
Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys (2008) 1.22
Nutrient restriction and radiation therapy for cancer treatment: when less is more. Oncologist (2013) 1.20
FGDP: functional genomics data pipeline for automated, multiple microarray data analyses. Bioinformatics (2004) 1.19
Biochemical and structural characterization of the Pak1-LC8 interaction. J Biol Chem (2008) 1.17
Progress in epidermolysis bullosa research: toward treatment and cure. J Invest Dermatol (2010) 1.16
CoGAPS: an R/C++ package to identify patterns and biological process activity in transcriptomic data. Bioinformatics (2010) 1.15
Activation of the NOTCH pathway in head and neck cancer. Cancer Res (2013) 1.15
Integrative discovery of epigenetically derepressed cancer testis antigens in NSCLC. PLoS One (2009) 1.14
Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment Cell Melanoma Res (2013) 1.13
Complex regulation of signal transducers and activators of transcription 3 activation in normal and malignant keratinocytes. Cancer Res (2004) 1.13
Promoter methylation in head and neck squamous cell carcinoma cell lines is significantly different than methylation in primary tumors and xenografts. PLoS One (2011) 1.12
ASAP: automated sequence annotation pipeline for web-based updating of sequence information with a local dynamic database. Bioinformatics (2003) 1.11
A Markov chain Monte Carlo technique for identification of combinations of allelic variants underlying complex diseases in humans. Genetics (2005) 1.11
Novel use of zebrafish as a vertebrate model to screen radiation protectors and sensitizers. Int J Radiat Oncol Biol Phys (2005) 1.11
Human papillomavirus in early laryngeal carcinoma. Laryngoscope (2009) 1.10
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumor. Mol Cancer Ther (2009) 1.10
Resistance of Akt kinases to dephosphorylation through ATP-dependent conformational plasticity. Proc Natl Acad Sci U S A (2011) 1.09
Metastasis-associated protein (MTA)1 enhances migration, invasion, and anchorage-independent survival of immortalized human keratinocytes. Oncogene (2002) 1.08
Specific sequences in p120ctn determine subcellular distribution of its multiple isoforms involved in cellular adhesion of normal and malignant epithelial cells. J Cell Sci (2002) 1.07
t4 workshop report: Pathways of Toxicity. ALTEX (2013) 1.06
Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther (2008) 1.06
Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care? Cancer Treat Rev (2012) 1.06
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor. PLoS One (2013) 1.06
Selectively starving cancer cells through dietary manipulation: methods and clinical implications. Future Oncol (2013) 1.05
Concomitant weekly cisplatin and radiotherapy for head and neck cancer. Jpn J Clin Oncol (2011) 1.04
Efficacy and patterns of failure for locally advanced cancer of the cervix treated with celebrex (celecoxib) and chemoradiotherapy in RTOG 0128. Int J Radiat Oncol Biol Phys (2007) 1.04
Inhibition of p73 function by Pifithrin-alpha as revealed by studies in zebrafish embryos. Cell Cycle (2008) 1.03
E-cadherin loss promotes the initiation of squamous cell carcinoma invasion through modulation of integrin-mediated adhesion. J Cell Sci (2006) 1.03
Giant cell tumors of the skull: a series of 18 cases and review of the literature. J Neurooncol (2013) 1.02
Matrix factorization for recovery of biological processes from microarray data. Methods Enzymol (2009) 1.02
Molecular profiling to optimize treatment in non-small cell lung cancer: a review of potential molecular targets for radiation therapy by the translational research program of the radiation therapy oncology group. Int J Radiat Oncol Biol Phys (2012) 1.02
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model. Clin Cancer Res (2006) 1.02
The insulin-like growth factor system as a potential therapeutic target in gastrointestinal stromal tumors. Cell Cycle (2008) 1.02
The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128. Int J Gynecol Cancer (2012) 1.01
Validation of lysyl oxidase as a prognostic marker for metastasis and survival in head and neck squamous cell carcinoma: Radiation Therapy Oncology Group trial 90-03. J Clin Oncol (2009) 1.00
Cells expressing partially unfolded R789C/p.R989C type II procollagen mutant associated with spondyloepiphyseal dysplasia undergo apoptosis. Hum Mutat (2008) 1.00
Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice. Cancer Res (2009) 0.99
Determination of strongly overlapping signaling activity from microarray data. BMC Bioinformatics (2006) 0.99
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
Malignant transformation of immortalized HaCaT keratinocytes through deregulated nuclear factor kappaB signaling. Cancer Res (2006) 0.98